All News
ACR20 - Day 2 Report
Saturday was the day 2 with many posters and live sessions at the 2020 Virtual ACR/ARP meeting. Here are a few of my highlights from day two:
Read Article
Another great thieves market imaging - whole body pain after starting antifungal? Check out TM17 for diagnosis! #acr20 @RheumNow https://t.co/8VIGi7mbMY
Eric Dein ejdein1 ( View Tweet)
Unilateral hip pain in a 27 yo male w/ hx of dermatomyositis on IVIG, MMF, & GC. MRI image below. What’s your diagnosis? Biopsy or no biopsy? Check out Thieves Market poster 19 by Dr. Son from @jhrheumatology. #ACR20 @RheumNow https://t.co/g9R1bB4LeS
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Dr @Juge_P_A @PhilippeDieude in abstr#1195 present that MUC5B promoter variant not associated with disease progression or need for transplant in RA-ILD. Interesting, as it is associated with both RA-ILD and IPF, and with a better prognosis in IPF #ACR20
@rheumnow https://t.co/2Kdpq73AIP
Richard Conway RichardPAConway ( View Tweet)
Dr @Juge_P_A @PhilippeDieude on potential role for MUC5B genotyping in risk stratification for RA-ILD. Makes sense but need to clarify exact role. Abst#1194 #ACR20 @rheumnow https://t.co/crLfz2duWF
Richard Conway RichardPAConway ( View Tweet)
Good images of multicentric reticulohistiocytosis: note the DIP involvement as a tip off! TM14 @RheumNow #ACR20. https://t.co/Za4X0WTdtb
Eric Dein ejdein1 ( View Tweet)
64 yo Indian F w/ previous dx of RA presents w/ skin lesions & arthritis (images below) in setting of high CRP, neg RF & CCP, ANA 1:80 speckled? What’s your diagnosis? Check our TM poster 14 for the answer! #ACR20 @RheumNow https://t.co/A11TDrwRga
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
PREVENT study: SEC provided clinically meaningful improvement in back pain, morning stiffness, fatigue, & physical function in TNFi-naïve nr-axSpA pts over 52 weeks. #ABS1340 #ACR20 @RheumNow https://t.co/RugzhqbY2A https://t.co/5kaZWoYk9t
Dr. Rachel Tate uptoTate ( View Tweet)
Gout ^CV events but hard to unravel as an independent risk as so many with gout have CRF, HTN, metabolic syndrome. But beware and get CV risk factors treated in gout pts abstr#950 @RheumNow @CRASCRRheum #ACR20 https://t.co/xYxE0xpCOj
Janet Pope Janetbirdope ( View Tweet)
Some really great & informative abstracts in #ANCA #vasculitis poster session! Incl work on thyroid disease such as ab#1433. This study confirmed the association with AAV but also showed PR3-ANCA is assoc. w/ less risk for thyroid disease.
#ACR20 @RheumNow
https://t.co/bMB0o8Eylo
Mrinalini Dey DrMiniDey ( View Tweet)
Dr Kronzer and @jeffsparks presenting on lifestyle and clinical risk factors for RA-ILD. Obesity, CRP >=10mg/L, poor function, and high education level appear to be risks. Also threshold pk/yr effect for smoking #ACR20 @rheumnow https://t.co/dM73lBLXVN
Richard Conway RichardPAConway ( View Tweet)
Don’t forget to look for microscopic colitis in spondyloarthritis. It’ll solve many of your unsolved questions. #ACR20 poster session @RheumNow https://t.co/M7JubMtZiB
Sole RetamozoSole ( View Tweet)
Thinking about Dr. Fauci's forecast for a vaccine to be deployed early 2021. If/when it is offered, would you receive it?
@RheumNow #ACR20
Robert B Chao, MD doctorRBC ( View Tweet)
Dr Egan presents 18-month data on use of anti-IL5 therapy in 13 EGPA patients. 50% reduction in steroid dose with anti-IL5. BVAS and asthma control questionnaire improved. 12 of 13 continued anti-IL5. @rheumnow #ACR20 Abstr#1427 https://t.co/qVy7Nb3OoA
Richard Conway RichardPAConway ( View Tweet)
Scurvy! Corkscrew hairs. Good exam question and we may still see it in the chips & sofa crowd and other poor eating habits. Learn from sailors re eating limes=limey. So have a twist of lemon or lime in your gin &tonic. If I guessed wrong oh well! @RheumNow @CRASCRRheum #ACR20 https://t.co/c8UN3bpPHC
Janet Pope Janetbirdope ( View Tweet)
Dr Giorgiutti and @Lupusreference present on prevalence of AAV in relation to silica exposure from quarries. Prevalence of GPA 2 fold higher in region with quarries vs city. Spatial association between quarries and GPA but not MPA/RLV. @rheumnow #ACR20 Abstr#1426 https://t.co/xHnOWCdXWe
Richard Conway RichardPAConway ( View Tweet)
Mepolizumab (anti-IL5) shown to be clinically beneficial and well-tolerated in the long-term for patients with #EGPA, with a 50% reduction in #steroid dose in the study cohort.
Abs#1427 #ACR20 @RheumNow #Vasculitis
https://t.co/elr6VR7447
Mrinalini Dey DrMiniDey ( View Tweet)
Dr Juge @Juge_P_A reports on prevalence of subclinical RA-ILD as identified by HRCT. At mean disease duration of 13 years 18.2% of patients had subclinical RA-ILD. @rheumnow #ACR20 Abstr#1199 https://t.co/VWKFxwFfIJ
Richard Conway RichardPAConway ( View Tweet)
RheumNow’s expanded coverage of the #ACR20 Annual meeting is sponsored in part by @Novartis. All content chosen by @RheumNow & its Faculty.
Dr. John Cush RheumNow ( View Tweet)
Dr Lee reports on risk of melanoma and NMSC risk in RA in cohort study using propensity score matching. No difference in risk between MTX and HCQ overall. Increase BCC in MTX (HR 1.32) but less SCC (HR 0.77) @rheumnow #ACR20 Abstr#1001 https://t.co/LDWgfGK9LS
Richard Conway RichardPAConway ( View Tweet)